SECURITIESAND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIESEXCHANGE ACT OF 1934
August, 2024
Commission File Number 1-15182
DR.REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annualreports
under cover of Form 20-F or Form 40-F.
Form20-F
x
Form 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-Kin paper as
permitted by Regulation S-T Rule 101(b)(1): ______
Note:
Regulation S-T Rule 101(b)(1) onlypermits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-Kin paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Note:
Regulation S-T Rule 101(b)(7) onlypermits the submission in paper of a Form
6-K if submitted to furnish a report or other document that the registrant
foreign private issuermust furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized(the registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securitiesare traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to theregistrant's security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or otherCommission filing on EDGAR.
Indicate by check mark whether by furnishing theinformation contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b)under the Securities Exchange Act of 1934.
Yes
¨
No
x
If "Yes" is marked, indicate below the file number assignedto registrant in
connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Description of Exhibits
Number
99.1 Intimation dated August 31, 2024
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
DR. REDDY'S LABORATORIES LIMITED
(Registrant)
Date: August 31, 2024 By: /s/ K Randhir Singh
Name: K Randhir Singh
Title: Company Secretary
3
Exhibit 99.1
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com
August 31, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015
This is to inform that the Company has learntabout orders dated August 30,
2024, of National Medical Products Administration, China and National Drug
Joint Procurement Office, China,made available through their website. The
details as required under Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements)Regulations, 2015 read with Schedule III Para A Sub
Para 20 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations,2015 are as hereunder:
a Name of the authority : National Medical Products
Administration, China (NMPA) and
National Drug Joint Procurement
Office, China (NDJPO)
b Nature and details : NMPA China recently conducted a remote inspection of the
of the action(s) Company's formulations manufacturing facility (FTO-3) for
taken, initiated Atomoxetine Hydrochloride Capsules, and concluded that the
or order(s) passed production quality management of Atomoxetine Hydrochloride
Capsules does not meet the requirements of China's "Good
Manufacturing Practice for Drugs (Revised in 2010)". The NMPA
has suspended the import, sale, and use of the Company's
Atomoxetine Hydrochloride Capsules effective August 30, 2024.
Further, NDJPO, having considered the said
order of the NMPA, has decided to cancel Dr.
Reddy's Laboratories Ltd.'s Atomoxetine
Hydrochloride Capsules "won" status and list the
company on the "Violation List", suspending
the company's eligibility to participate in
national centralized drug procurement activities
from August 30, 2024 to February 28, 2026.
c Date of receipt of direction or : Both NMPA and NDJPO orders
order, including any ad-interim are dated August 30, 2024
or interim orders, or any other
communication from the authority
d Details of the violation(s)/ : As detailed above in para b
contravention(s)
committed or alleged
to be committed
e Impact on financial, operation or : The Company is in the
other activities of the listed process of ascertaining
entity, quantifiable in monetary the monetary impact
terms to the extent possible of the said orders.
This is for your information and record.
Thanking you.
Yours faithfully,
For
Dr. Reddy's Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
{graphic omitted}
{graphic omitted}
{graphic omitted}